Armata Pharmaceuticals, Inc.
ARMP
$0.10
Change (1 day)
$4.48
Year High
$1.90
Year Low
Categories
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Armata Pharmaceuticals, Inc. (ARMP) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 3.36 M | 106.85 M | 142.03 M | 109.96 M | 19.15 M |
| 2022 | 1.94 M | 33.96 M | 59.75 M | 95.83 M | 27.05 M |
| 2021 | 2.99 M | 27.7 M | 44.37 M | 69.77 M | 15 M |
| 2020 | 561 K | 3.5 M | 20.66 M | 39.52 M | 10.85 M |
| 2019 | -3,170,000 | 10.86 M | 25.45 M | 6.66 M |